These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28436001)

  • 1. Gait instability in valproate-treated patients: Call to measure ammonia levels.
    Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
    Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
    Mojumder DK; De Oleo RR
    Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
    Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
    Habhab SF; Ulvin LB; Taubøll E; Svalheim S; Olsen KB; Horn MA; Heuser K
    Epilepsy Behav; 2020 Oct; 111():107193. PubMed ID: 32759060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
    Kwack DW; Kim DW
    Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
    Panda S; Radhakrishnan K
    J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
    Mehndiratta MM; Mehndiratta P; Phul P; Garg S
    J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperammonemic encephalopathy associated with valproate acid].
    Osuna MT; Burcet J; Ramió L; Ustrell X; Silva Y; Molins A
    Neurologia; 2003; 18(6):347-50. PubMed ID: 12838456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
    Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
    Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.
    Vossler DG; Wilensky AJ; Cawthon DF; Kraemer DL; Ojemann LM; Caylor LM; Morgan JD
    Epilepsia; 2002 Feb; 43(2):154-9. PubMed ID: 11903461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
    Cheng M; Tang X; Wen S; Yue J; Wang H
    Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study.
    Woo PYM; Woo AWY; Lam SW; Ko NMW; Ho JWK; Chu ACH; Kwan MCL; Chan Y; Wong HT; Chan KY
    World Neurosurg; 2020 Dec; 144():e597-e604. PubMed ID: 32916358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.